drugset / Trial / NCT04837196
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a single agent and in combination with pembrolizumab. This study also evaluated other measures of anticancer activity of ASP7517 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.
Timeline
- Start
- 2021-11-11
- Primary completion
- 2024-06-21
- Completion
- 2024-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASP7517 | Unknown | 1e+07 cells | Intravenous |
| Subject | ASP7517 | Unknown | 1e+08 cells | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |